Antioxidant effects of statins

Lynn L. Stoll, Michael L. McCormick, Gerene M. Denning, Neal Lee Weintraub

Research output: Contribution to journalReview article

91 Citations (Scopus)

Abstract

Statins, a group of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are widely used in clinical practice for their efficacy in producing significant reductions in plasma cholesterol and LDL cholesterol and in reducing morbidity and mortality from cardiovascular disease. However, several large clinical trials have suggested that the cholesterol-lowering effects of statins may not completely account for the reduced incidence of cardiovascular disease seen in patients receiving statin therapy. A number of recent reports have shown that statins may also have important antiinflammatory effects, in addition to their effects on plasma lipids. Since inflammation is closely linked to the production of reactive oxygen species (ROS), the molecular basis of the observed antiinflammatory effects of statins may relate to their ability block the production and/or activity of ROS. In this review, we will discuss both the inhibition of ROS generation by statins, through interference with NAD(P)H oxidase expression and activity, and the actions of statins that serve to blunt the damaging effects of these radicals, including effects on antioxidant enzymes, lipid peroxidation, LDL cholesterol oxidation and nitric oxide synthase. These antioxidant effects of statins likely contribute to their clinical efficacy in treating cardiovascular disease as well as other chronic conditions associated with increased oxidative stress in humans.

Original languageEnglish (US)
Pages (from-to)975-989
Number of pages15
JournalDrugs of Today
Volume40
Issue number12
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Antioxidants
Reactive Oxygen Species
Cardiovascular Diseases
LDL Cholesterol
Anti-Inflammatory Agents
Cholesterol
NADPH Oxidase
Nitric Oxide Synthase
Lipid Peroxidation
Oxidoreductases
Oxidative Stress
Clinical Trials
Inflammation
Morbidity
Lipids
Mortality
Incidence
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Stoll, L. L., McCormick, M. L., Denning, G. M., & Weintraub, N. L. (2004). Antioxidant effects of statins. Drugs of Today, 40(12), 975-989. https://doi.org/10.1358/dot.2004.40.12.872573

Antioxidant effects of statins. / Stoll, Lynn L.; McCormick, Michael L.; Denning, Gerene M.; Weintraub, Neal Lee.

In: Drugs of Today, Vol. 40, No. 12, 01.12.2004, p. 975-989.

Research output: Contribution to journalReview article

Stoll, LL, McCormick, ML, Denning, GM & Weintraub, NL 2004, 'Antioxidant effects of statins', Drugs of Today, vol. 40, no. 12, pp. 975-989. https://doi.org/10.1358/dot.2004.40.12.872573
Stoll, Lynn L. ; McCormick, Michael L. ; Denning, Gerene M. ; Weintraub, Neal Lee. / Antioxidant effects of statins. In: Drugs of Today. 2004 ; Vol. 40, No. 12. pp. 975-989.
@article{9e6386cc593c492c937bcb2b7b1f7ce2,
title = "Antioxidant effects of statins",
abstract = "Statins, a group of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are widely used in clinical practice for their efficacy in producing significant reductions in plasma cholesterol and LDL cholesterol and in reducing morbidity and mortality from cardiovascular disease. However, several large clinical trials have suggested that the cholesterol-lowering effects of statins may not completely account for the reduced incidence of cardiovascular disease seen in patients receiving statin therapy. A number of recent reports have shown that statins may also have important antiinflammatory effects, in addition to their effects on plasma lipids. Since inflammation is closely linked to the production of reactive oxygen species (ROS), the molecular basis of the observed antiinflammatory effects of statins may relate to their ability block the production and/or activity of ROS. In this review, we will discuss both the inhibition of ROS generation by statins, through interference with NAD(P)H oxidase expression and activity, and the actions of statins that serve to blunt the damaging effects of these radicals, including effects on antioxidant enzymes, lipid peroxidation, LDL cholesterol oxidation and nitric oxide synthase. These antioxidant effects of statins likely contribute to their clinical efficacy in treating cardiovascular disease as well as other chronic conditions associated with increased oxidative stress in humans.",
author = "Stoll, {Lynn L.} and McCormick, {Michael L.} and Denning, {Gerene M.} and Weintraub, {Neal Lee}",
year = "2004",
month = "12",
day = "1",
doi = "10.1358/dot.2004.40.12.872573",
language = "English (US)",
volume = "40",
pages = "975--989",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "12",

}

TY - JOUR

T1 - Antioxidant effects of statins

AU - Stoll, Lynn L.

AU - McCormick, Michael L.

AU - Denning, Gerene M.

AU - Weintraub, Neal Lee

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Statins, a group of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are widely used in clinical practice for their efficacy in producing significant reductions in plasma cholesterol and LDL cholesterol and in reducing morbidity and mortality from cardiovascular disease. However, several large clinical trials have suggested that the cholesterol-lowering effects of statins may not completely account for the reduced incidence of cardiovascular disease seen in patients receiving statin therapy. A number of recent reports have shown that statins may also have important antiinflammatory effects, in addition to their effects on plasma lipids. Since inflammation is closely linked to the production of reactive oxygen species (ROS), the molecular basis of the observed antiinflammatory effects of statins may relate to their ability block the production and/or activity of ROS. In this review, we will discuss both the inhibition of ROS generation by statins, through interference with NAD(P)H oxidase expression and activity, and the actions of statins that serve to blunt the damaging effects of these radicals, including effects on antioxidant enzymes, lipid peroxidation, LDL cholesterol oxidation and nitric oxide synthase. These antioxidant effects of statins likely contribute to their clinical efficacy in treating cardiovascular disease as well as other chronic conditions associated with increased oxidative stress in humans.

AB - Statins, a group of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are widely used in clinical practice for their efficacy in producing significant reductions in plasma cholesterol and LDL cholesterol and in reducing morbidity and mortality from cardiovascular disease. However, several large clinical trials have suggested that the cholesterol-lowering effects of statins may not completely account for the reduced incidence of cardiovascular disease seen in patients receiving statin therapy. A number of recent reports have shown that statins may also have important antiinflammatory effects, in addition to their effects on plasma lipids. Since inflammation is closely linked to the production of reactive oxygen species (ROS), the molecular basis of the observed antiinflammatory effects of statins may relate to their ability block the production and/or activity of ROS. In this review, we will discuss both the inhibition of ROS generation by statins, through interference with NAD(P)H oxidase expression and activity, and the actions of statins that serve to blunt the damaging effects of these radicals, including effects on antioxidant enzymes, lipid peroxidation, LDL cholesterol oxidation and nitric oxide synthase. These antioxidant effects of statins likely contribute to their clinical efficacy in treating cardiovascular disease as well as other chronic conditions associated with increased oxidative stress in humans.

UR - http://www.scopus.com/inward/record.url?scp=12344280212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344280212&partnerID=8YFLogxK

U2 - 10.1358/dot.2004.40.12.872573

DO - 10.1358/dot.2004.40.12.872573

M3 - Review article

VL - 40

SP - 975

EP - 989

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 12

ER -